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Abstract In MCF-7 breast cancer cells, estradiol (E2) and pure
antiestrogen RU 58668 down-regulate the estrogen receptor
(ER). Interestingly, the protein synthesis inhibitor cycloheximide
(CHX) abrogated solely the effect of E2 suggesting a selective
difference in the degradation of the receptor induced by
estrogenic and antiestrogenic stimulations. A panel of lysosome
inhibitors (i.e. bafilomycin, chloroquine, NH4Cl, and monensin),
calpain inhibitors (calpastatin and PD 150606) and proteasome
inhibitors (lactacystin and proteasome inhibitor I) were tested to
assess this hypothesis. Among all inhibitors tested, lactacystin
and proteasome inhibitor I were the sole inhibitors to abrogate
the elimination of the receptor induced by both E2 and RU
58668; this selective effect was also recorded in cells prelabeled
with [3H]tamoxifen aziridine before exposure to these ligands.
Hence, differential sensitivity to CHX seems to be linked to the
different mechanisms which target proteins for proteasome-
mediated destruction. Moreover, the two tested proteasome
inhibitors produced a slight increase of ER concentration in cells
not exposed to any ligand, suggesting also the involvement of
proteasome in receptor turnover.
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1. Introduction
There is a continuous turnover of proteins in eukaryotic
cells, with individual half-life varying from a few minutes to
weeks [1]. Among proteins with the shortest half-lives are key
regulatory factors. Metabolic instability of these factors al-
lows a rapid adjustment of their concentrations and/or sub-
unit composition through changes in their rate of synthesis or
degradation.
The estrogen receptor (ER) is a transcriptional factor which
regulates cellular genes upon ligand binding [2,3]. While ER
activation and function have been extensively studied, knowl-
edge of the mechanisms governing its concentration is rather
weak. The half-life of ER is about 3 to 4 h, as revealed by
pulse-chase experiments employing covalently attached lig-
ands or dense amino acid incorporation-density shift techni-
ques [4^6]. Analysis of the underlying degradation process is
of importance since it governs the receptor level and, conse-
quently, in£uences the response of the cells to estrogens as
well as their antagonists [7,8].
Mammalian cells contain two distinct proteolytic pathways:
lysosomal and non-lysosomal [9]. The ability of each system
to partly or completely degrade proteins, re£ects the complex-
ity of intracellular proteolysis [10,11]. With regard to the ly-
sosomal pathway, several mechanisms for the uptake of cel-
lular proteins into lysosomes have been described including
the recognition of speci¢c amino acid sequences [12]. Of
note, among non-lysosomal systems, calpains which are cal-
cium-dependent cysteine proteases, were reported to hydrolyse
ER extracted from uterine and breast cancer tissues [13,14].
There are at least two types of calpains, W- and m-calpains
(also designed as calpain I and calpain II), requiring respec-
tively a micromolar and a milimolar concentration of Ca2
for activation [15]. In addition to calpains, cells contain an-
other major non-lysosomal proteinase system known as the
26S proteasome complex [16^18]. Although the latter is pre-
dominantly a cytosolic system, it has also been detected in the
nucleus, and puri¢ed from erythrocyte membranes [19,20].
The ‘20S catalytic core’ of the proteasome contains several
subunits (K- and L-subunits) that allow specialized proteolytic
functions. These subunits exhibit up to ¢ve di¡erent peptidase
activities, including sites that preferentially cleave after basic,
hydrophobic, or acidic residues [21^23].
In the present study, we tried to elucidate the degree of
implication of these pathways in the degradation of ER.
Our study was conducted on MCF-7 breast cancer cells which
have been widely used to study the regulation of ER level
under both estrogenic and antiestrogenic stimulations. In
these cells, estrogens (i.e. estradiol, E2 or diethylstilbestrol)
and pure antiestrogens (i.e. RU 58668 or ICI 164384), de-
crease ER level within a few hours (a down-regulation process
also called ‘processing’ [24,25]). Protein synthesis inhibitors
(i.e. cycloheximide ‘CHX’ and puromycin) abrogate the
down-regulating e¡ect of E2 without interfering with receptor
activation and subsequent transcription ability [26]. Interest-
ingly, the inhibitory e¡ect of CHX did not hold for the re-
ceptor elimination induced by pure antiestrogens [25]. This
observation led us to also analyse whether ER degradation
induced by E2 and RU 58668 is linked to di¡erent proteolytic
pathways.
2. Materials and methods
2.1. Reagents
[3H]E2 (95 Ci/mmol) and [3H]tamoxifen aziridine ([3H]TAZ) (20 Ci/
mmol) were purchased from Amersham (UK). Unlabeled E2, cyclo-
heximide (CHX), puromycin, NH4Cl, monensin, chloroquine, ba¢lo-
mycin and anti-rat IgG agarose were obtained from Sigma (St. Louis,
MO, USA). Lactacystin, proteasome inhibitor I, calpastatin and cal-
pain inhibitor PD 150606 were purchased from Calbiochem (San Die-
go, CA, USA). RU 58668 was a gift of Roussel-Uclaf (Romainville,
France). H222 rat anti-ER monoclonal antibody was provided by Dr.
D. Cotter (Abbott laboratories, North Chicago, IL, USA).
2.2. Cell culture
MCF-7 cells were maintained in culture in Falcon T 75 £asks at
37‡C in MEM supplemented with 10% heat-inactivated fetal calf se-
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rum (56‡C, 1 h), L-glutamine, penicillin, streptomycin and gentamicin
at the usual concentration [27]. Experiments were conducted with 10%
fetal calf serum stripped of endogenous hormones by a dextran-coated
charcoal (DCC) treatment [28].
2.3. Assessment of proteolytic inhibitors on ligand-induced ER
elimination
MCF-7 cells from a near-con£uent culture were incubated for up to
6 h either with 1 nM E2 or 10 nM RU 58668 in the presence or
absence of ba¢lomycin at 10 WM, lactacystin at 10 WM or calpastatin
at 0.05 Wg/ml. At the end of incubation, cells were washed twice with
Ca2/Mg2 free Hank’s balanced salt solution (HBSS) and harvested
by incubation with 1 mM EDTA in the same bu¡er (10 to 15 min).
All subsequent steps were performed at 0^4‡C. After centrifugation
(800Ug, 10 min), the cell pellets were washed successively with Hank’s
solution and a phosphate bu¡er (10 mM potassium phosphate pH 7.4,
10% glycerol, 10 mM thioglycerol and 1.5 mM EDTA). Cellular ex-
tracts were obtained by freezing these pellets at 370‡C and subse-
quent homogenization in 1 ml of this phosphate bu¡er containing
500 mM KCl; cellular debris were removed by ultracentrifugation
(100 000Ug ; 1 h). ER contents of these extracts were measured by
the Abbott’s enzyme immunoassay (ER-EIA); values were always
within the linear range of the kit standard (0^500 fmol/ml). Protein
contents of the extracts were assessed by the coomassie Protein Re-
agent Assay (Pierce, Rockford, IL, USA) using bovine serum albumin
(Sigma, fraction V) as standard. ER concentration (fmoles/mg pro-
tein) was expressed as a percentage of the level in untreated cells
(control condition).
2.4. Assessment of proteolytic inhibitors on ligand-induced
[3H]TAZ-ER complex elimination
MCF-7 cells were incubated for 1 h with 20 nM [3H]TAZ; for non-
speci¢c binding assessment, additional cells were preincubated for
30 min with 1 WM unlabeled E2 and maintained with the hormone
during the whole [3H]TAZ labeling period. After removal of the me-
dium, cells were rinsed three times with 10 ml of MEM at 37‡C. Fresh
medium containing 1 nM E2 or 10 nM RU 58668 either with or
without ba¢lomycin at 10 WM, lactacystin at 10 WM or calpastatin
at 0.05 Wg/ml was then added and the culture pursued up to 6 h.
Medium was ¢nally removed and the cells harvested, suspended and
extracted as described above. Extracts were added with dimethylform-
amide (¢nal concentration 7%) and submitted to immunoprecipitation
with H222 anti-ER (1 Wl/ml, 2 h at 4‡C). Immune complexes were
adsorbed on anti-rat IgG agarose (overnight incubation at 4‡C), cen-
trifuged and washed three times in 1 ml of 20 mM Tris-HCl, pH 7.4
containing 500 mM KCl, 1 mM DTT, 50 mM NaF, 10 mM
Na2MoO4. Pellets were resuspended in 200 Wl of the same bu¡er
and the radioactivity of a 120 Wl aliquot measured by liquid scintilla-
tion counting with an e⁄ciency ofV40% (Scintillation £uid: Ecoscint
H; National Diagnostic, Atlanta, GA, USA). Speci¢c [3H]TAZ label-
ing was calculated and the values were expressed as a percentage of
the level in control cells.
2.5. Assessment of proteolytic inhibitors on [3H]E2 binding capacity
MCF-7 cells were incubated with 1 nM [3H]E2 in the presence of a
given inhibitor for up to 6 h (CHX at 50 WM, NH4Cl at 10 mM,
monensin at 10 WM, chloroquine at 100 WM, ba¢lomycin at 10 WM,
FEBS 21811 29-3-99
Fig. 1. E¡ect of CHX on the ligand-induced ER elimination. MCF-7 cells were incubated up to 6 h with 1 nM E2 or 10 nM RU 58668 in the
presence or absence of 50 WM CHX (L: ligand). After removal of the medium, cells were washed, harvested, extracted and their ER contents
measured by the Abbott’s enzyme immunoassay (ER-EIA). Control cells were incubated without drugs. The data refer to the mean þ S.D. of
three separate experiments (CTR: 760, 786, 804 fmoles/mg protein = 100%). Additionally, cells were incubated for 3 h with E2 or RU 58668 at
concentrations ranging from 1 nM to 1 WM in the presence or absence of 50 WM CHX; residual ER contents were similarly measured by EIA.
A. El Khissiin, G. Leclercq/FEBS Letters 448 (1999) 160^166 161
lactacystin at 10 WM, proteasome inhibitor I at 0.1 nM, calpastatin at
0.05 Wg/ml and PD 150606 at 0.5 WM). At the given concentration for
the duration of our experiment, all these drugs failed to show any
cytotoxic e¡ect (MTT assay). Non-speci¢c binding was established by
a parallel incubation with a 500-fold excess of unlabeled E2. Control
[3H]E2 labeled cells were maintained without any inhibitor. At the end
of the incubation, medium was removed and the cells washed twice
with ice-cold saline solution (HBSS). Bound [3H]E2 was extracted
from the monolayers by an incubation in 250 Wl ethanol at room
temperature (20 min) and measured (200 Wl of extract) by scintillation
counting. Speci¢cally bound [3H]E2 was calculated from the di¡erence
of incorporated radioactivity after incubation in the presence and
absence of unlabeled E2. Data were expressed as percentages of spe-
ci¢cally incorporated [3H]E2 in the control condition.
In an additional experiment, MCF-7 cells were preincubated up to
6 h with 10 WM lactacystin or 0.1 nM proteasome inhibitor I before
being exposed to [3H]E2 ; control cells were maintained without drugs.
After removal of the medium, cells were rinsed twice with MEM at
37‡C and the culture pursued for 1 h with [3H]E2 and one of these two
inhibitors. Speci¢c [3H]E2 incorporation was subsequently determined
as above. At the end of experiment, ER levels were also measured by
Abbott’s enzyme immunoassay on both control and treated cells (6 h
of incubation).
3. Results
3.1. E¡ect of protein synthesis inhibitor on ligand-induced ER
elimination
Treatment of MCF-7 cells with either 1 nM E2 or 10 nM
RU 58668 is known to produce a rapid decrease of their ER
level as con¢rmed here by Abbott’s enzyme immunoassays.
As expected addition of 50 WM CHX to the medium at the
same time as these ligands abrogated solely the e¡ect of E2
(Fig. 1, left panel). This property could not be ascribed to a
di¡erence of ligand concentration since it occurred for both
E2 and RU 58668 on a wide range of concentrations (Fig. 1,
right panel). Interestingly, similar results were observed with
50 WM puromycin (fmoles/mg protein, % of control : E2/
Pur = 79, RU 58668/Pur = 18; n = 2) clearly establishing the
involvement of protein synthesis in the phenomenon. Hence,
a major di¡erence in the metabolic degradative pathways fol-
lowing the binding of these ligands to ER should be consid-
ered.
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Fig. 2. E¡ect of proteolytic inhibitors on ligand-induced ER elimination. MCF-7 cells were incubated for 1 to 6 h either with 1 nM E2 or
10 nM RU 58668 in the presence or absence of 10 WM ba¢lomycin, 0.05 Wg/ml calpastatin or 10 WM lactacystin (L: ligand). After removal of
the medium, cells were washed, harvested, extracted and their ER contents measured by the Abbott’s enzyme immunoassay (ER-EIA). Control
cells were incubated without drugs. The data refer to the mean þ S.D. of three separate experiments (CTR: 791, 816, 843 fmoles/mg pro-
tein = 100%).
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3.2. E¡ects of protease inhibitors on the ligand-induced ER
elimination
Since CHX and puromycin were reported to inhibit protein
hydrolysis by decreasing the amounts of lysosomal enzymes
[29,30], we investigated if these organelles could play a role in
ER degradation speci¢cally under E2 stimulation. In the pres-
ence of ba¢lomycin, a speci¢c inhibitor of the lysosomal pro-
ton pump [31], E2 as well as RU 58668 maintained their
ability to decrease ER concentration suggesting that lysoso-
mal proteases were not involved in this process (Fig. 2).
Hence, ER elimination seems in each case to proceed via an
extralysosomal proteolytic system. The fact that ER is a sub-
strate of calpain [13] led us to examine the involvement of the
latter. The results obtained with the use of an endogenous
calpain-speci¢c inhibitor, calpastatin [32], did not support
this possibility (Fig. 2). We then assessed the potential impli-
cation of the proteasome complex in ER elimination. Re-
markably, lactacystin (a highly speci¢c, irreversible, protea-
some inhibitor [33]), abrogated ER elimination induced by
both E2 and RU 58668 (Fig. 2). Interestingly, ER prelabeled
with [3H]TAZ before exposure to E2 or RU 58668, and in the
presence of these various proteolytic inhibitors, behaved sim-
ilarly: while lactacystin suppressed the elimination of the
[3H]TAZ-ER complexes, ba¢lomycin and calpastatin ap-
peared ine¡ective (Fig. 3). Hence, the proteasome complex
appears to be always implicated in ER degradation, even
when its hormone binding site is covalently labeled with
[3H]TAZ and is therefore not accessible to the ligands; in
such a case, elimination depends upon the association of these
ligands with newly synthesized receptors [4].
3.3. E¡ects of protease inhibitors on the binding of [3H]E2 to
ER
Assessment of the e¡ect of protease inhibitors on the ca-
pacity of MCF-7 cells to incorporate [3H]E2 con¢rmed our
enzyme immunological data: four lysosomal inhibitors (i.e.
chloroquine, NH4Cl, ba¢lomycin and monensin which all in-
hibit cathepsin B activity, data not shown), as well as two
calpain inhibitors (i.e. calpastatin or PD 150606), failed to
impede the diminution of speci¢c [3H]E2 binding of the cells.
On the contrary, two proteasomal inhibitors (i.e. lactacystin
and proteasome inhibitor I) maintained the [3H]E2-ER com-
plexes (Fig. 4). Hence, proteasome inhibitors, while inhibiting
the E2-induced elimination of the ER peptide, did not inter-
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Fig. 3. E¡ect of proteolytic inhibitors on the ligand-induced [3H]TAZ-ER complex elimination. MCF-7 cells were labeled with 20 nM [3H]TAZ
for 1 h and subsequently exposed either to 1 nM E2 or 10 nM RU 58668 in the presence or absence of 10 WM ba¢lomycin, 0.05 Wg/ml calpas-
tatin or 10 WM lactacystin for the indicated time (L: ligand). After removal of the medium, cells were washed, harvested, extracted and
[3H]TAZ-ER complexes were selectively immunoadsorbed with H222 anti-ER monoclonal antibody and their radioactivity measured. The data
refer to the mean þ S.D. of three separate experiments (CTR: 7989, 8835, 8693 dpm = 100%).
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fere with its ability to bind the hormone. As expected, control
cells treated with CHX also maintained their [3H]E2 binding
capacity.
3.4. E¡ect of proteasome inhibitors on the ER turnover
Since the proteasome is involved in the turnover of several
regulatory proteins, we investigated whether the concentration
of the free (unbound) ER was similarly regulated by this pro-
teolytic complex. To this end, MCF-7 cells were preincubated
for up to 6 h with lactacystin or proteasome inhibitor I before
being labeled with [3H]E2 (1 h of incubation). Both drugs
induced a slight increase of [3H]E2 incorporation, which cor-
related with a receptor increase established by enzyme immu-
noassay (value at 6 h) (Fig. 5). Hence, the proteasome also
appeared to be implicated in ER turnover.
4. Discussion
In MCF-7 cells, estrogens (E2) and antiestrogens (RU
58668) bind to the same receptor; however, subsequent
down-regulation of the corresponding complexes seems to
proceed through distinct mechanisms: while CHX largely ab-
rogates the E2-ER elimination, it is totally ine¡ective on RU
58668-ER elimination [25].
All the speci¢c lysosomal inhibitors tested here, whatever
their mode of action, were ine¡ective in presence of both E2
and RU 58668 indicating that the lysosomal pathway is not
implicated in their induced degradation mechanism. There-
fore, the speci¢c inhibitory e¡ect of CHX observed with E2
would not be related to a blockade of synthesis of lysosomal
proteinases, nor to the production of (a) factor(s) required for
ER uptake into lysosomes.
Various transcription factors, including AP1 (c-Fos/c-Jun),
ATF/CREB and AP3, are cleaved by m-calpain to produce
partial digestion products [34,35]. This property raises the
possibility that calpain could be involved in the turnover of
transcription factors. On the other hand, most of the short-
lived proteins contain one or more regions rich in proline (P),
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Fig. 5. E¡ect of proteasome inhibitors on the ER turnover rate. MCF-7 cells were incubated with either 10 WM lactacystin or 0.1 nM protea-
some inhibitor I. At indicated times, medium was removed and replaced by fresh medium containing 1 nM [3H]E2 and each inhibitor. After 1
h of incubation, speci¢cally incorporated [3H]E2 was extracted and measured. Control cells were maintained without inhibitors. ER contents
were also determined by the Abbott’s enzyme immunoassay (ER-EIA) after 6 h of exposure to each inhibitor. The data refer to the
mean þ S.D. of three separate experiments (CTR: 7352, 7534, 7728 dpm = 100%). *ER-EIA values; % of control (CTR = 823, 850 fmoles/mg
protein).
Fig. 4. E¡ect of proteolytic inhibitors on [3H]E2 binding capacity. MCF-7 cells were incubated with 1 nM [3H]E2 in the absence or presence of
a given inhibitor (50 WM CHX, 100 WM chloroquine, 10 mM NH4Cl, 10 WM ba¢lomycin, 10 WM monensin, 0.05 Wg/ml calpastatin, 0.5 WM
PD 150606, 10 WM lactacystin and 0.1 nM proteasome inhibitor I). At indicated times, speci¢cally incorporated [3H]E2 was extracted and
measured. The data refer to the mean þ S.D. of three separate experiments (CTR: 7012, 7502, 7974 dpm = 100%).
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glutamic acid (E) and aspartic acid (D), serine (S) and threo-
nine (T), known as PEST regions [36]. These regions are rec-
ognized by (a) speci¢c protease(s) including calpains [37].
Computer sequence analysis of the human ER revealed a
PEST sequence within its carboxyl terminus (F domain) [38]
suggesting a possible in£uence of this region in the stability of
the receptor since calpain has been reported to hydrolyse the
cytosolic ER. Calpastatin, an endogenous inhibitor of calpain
I as well as PD 150606, a synthetic inhibitor of calpain I and
calpain II [39] were found to be ine¡ective in blocking ER
degradation induced by both E2 and RU 58668, which is
against the implication of the calpain system in the phenom-
enon. In fact, this observation is in agreement with data pub-
lished by Katzenellenbougen, who demonstrated that the
PEST region of ER is not a feature determining its degrada-
tion rate [38]. The potential role of calpains in ER function
remains unknown. One may speculate that they allow the
emergence of speci¢c cleavage ER products which accomplish
functions distinct from those of the native receptor.
In our experiments, elimination of ER by E2 or RU 58668
is always prevented by proteasome inhibitors. Hence, the pro-
teasome appears to be the major proteolytic pathway for the
estrogenic and antiestrogenic induced degradative process,
raising the question of the selective inhibition by CHX. Pro-
teasomal degradation does not only require an active multi-
proteinase complex, but also a signal for substrate targeting
[36,40,41]. In this regard, the best characterized mechanism is
the ubiquitin system: ¢rst, ubiquitin is added to the target
protein by successive enzymatic reactions, then the tagged
protein is ¢nally degraded by the proteasome [42,43]. Accord-
ing to this point of view, we suggest that E2 may induce at
least one or more of these enzymes, and that CHX may in-
£uence on their synthesis. This suggestion would not hold for
the pure antiestrogen RU 58668 since the RU 58668-ER com-
plex degradation appears to be independent of protein syn-
thesis. Such ubiquitin-independent recognition may occur
through direct interaction of ER with the proteasome [44],
its indirect association through other factors [45], or its inter-
action via a more generalized ubiquitin-independent tagging
mechanism (e.g. phosphorylation, methylation). On the other
hand, the subunit composition of the mammalian proteasome
core involves several types of subunits (14 di¡erent K- and L-
like polypeptides) as well as multiple distinct catalytic centers
(¢ve types of protease activities are associated with each com-
plex). In this regard, it has been reported that interferon-Q,
which enhances antigen presentation, induces the expression
of three L-subunits of the proteasome [46,47], which are in-
corporated into the latter in the place of homologous, normal
subunits. The resulting proteasome cleaves preferentially after
hydrophobic and basic residues. The possibility that E2 acts
similarly is an alternative explanation for the selective sensi-
tivity to CHX.
Our work clearly shows that ER elimination under E2 and
RU 58668 stimulations proceeds through the proteasomal
pathway. We suggest two proteasomal uptake mechanisms
which di¡er according to the nature of the ligand: a mecha-
nism blocked by CHX and puromycin which would contrib-
ute to the physiological autodown-regulation of the receptor
under estrogenic stimulation, and a mechanism independent
of protein synthesis, which may be implicated in the e¡ect of
antiestrogenic treatments. It now remains to identify the cor-
responding regulatory signals as well as the step(s) at which
CHX acts to explain its selective inhibitory e¡ect in the pres-
ence of estrogens.
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